Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238613 | 0.86 | KCNH2 (0.43) | MAPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL1237720 | 0.85 | SOS1 (0.41) | MAPTKCNH2NR4A2SSTR5HRH4 | |
| SCHEMBL1238612 | 0.84 | NPC1 (0.43) | MAPT | |
| SCHEMBL1238558 | 0.82 | KCNH2 (0.39) | MAPTKCNH2NR4A2SSTR5HRH4 | |
| SCHEMBL8294206 | 0.81 | KCNH2 (0.43) | MAPTKCNH2NR4A2SSTR5HRH4 | |
| SCHEMBL1237482 | 0.81 | ACSS2 (0.41) | MAPTKCNH2 | |
| SCHEMBL8294929 | 0.81 | KCNH2 (0.41) | MAPTKCNH2NR4A2SSTR5HRH4 | |
| SCHEMBL8294932 | 0.81 | SSTR5 (0.37) | MAPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL12909078 | 0.81 | KCNH2 (0.43) | MAPTKCNH2NR4A2SSTR5HRH4 | |
| SCHEMBL8292644 | 0.81 | KCNH2 (0.45) | MAPTKCNH2NR4A2SSTR5HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-8278455-B2 | 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| EP-1697347-B1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2011-02-23 | — | — | EP | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | BONFANTI JEAN-FRANCOIS | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093502-A1 | 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 | SCD 1507/4885MAPT 4884/4885CASP3 1726/4885 |
| US-20090062278-A1 | 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 | SCD 943/4885MAPT 4885/4885CASP3 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.